MedTrace Logo

Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder

NCT01912391 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-10-08

No results posted yet for this study

Summary

Selegiline is superior to placebo in improving psychological and physical functioning in patients with Borderline Personality Disorder.

Conditions

  • Borderline Personality Disorder

Interventions

DRUG

Selegiline

The Study Drug known as either selegiline 12 mg patch or matching placebo patch will be administered daily beginning at Visit 2 for the duration of 12 weeks.

DRUG

Placebo (for Selegiline)

Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch

Sponsors & Collaborators

  • Mood and Anxiety Research, Inc

    lead OTHER

Principal Investigators

  • Paul J Markovitz, MD, PhD · Mood and Anxiety Research, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01912391 on ClinicalTrials.gov